Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction.

Ceraudo E, Hierso R, Tan YV, Murail S, Rouyer-Fessard C, Nicole P, Robert JC, Jamin N, Neumann JM, Robberecht P, Laburthe M, Couvineau A.

FASEB J. 2012 May;26(5):2060-71. doi: 10.1096/fj.11-196444. Epub 2012 Jan 30.

PMID:
22291440
2.

VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling.

Passemard S, El Ghouzzi V, Nasser H, Verney C, Vodjdani G, Lacaud A, Lebon S, Laburthe M, Robberecht P, Nardelli J, Mani S, Verloes A, Gressens P, Lelièvre V.

J Clin Invest. 2011 Aug;121(8):3071-87. doi: 10.1172/JCI43824.

3.

Evidence for a direct and functional interaction between the regulators of G protein signaling-2 and phosphorylated C terminus of cholecystokinin-2 receptor.

Langer I, Tikhonova IG, Boulègue C, Estève JP, Vatinel S, Ferrand A, Moroder L, Robberecht P, Fourmy D.

Mol Pharmacol. 2009 Mar;75(3):502-13. doi: 10.1124/mol.108.051607. Epub 2008 Dec 8.

PMID:
19064631
4.

Cell surface targeting of VPAC1 receptors: evidence for implication of a quality control system and the proteasome.

Langer I, Leroy K, Gaspard N, Brion JP, Robberecht P.

Biochim Biophys Acta. 2008 Sep;1783(9):1663-72. doi: 10.1016/j.bbamcr.2008.03.013. Epub 2008 Apr 8.

5.

Effect of positive charge in VIP 16gamma-glutamyl diamino derivatives on hVPAC1 and hVPAC2 receptor function.

de Maria S, Metafora V, Metafora S, Ravagnan G, Cartení M, Pontoni G, Facchiano A, Lepretti M, Severino B, Caliendo G, Santagada V, Langer I, Robberecht P.

J Pept Sci. 2008 Jan;14(1):102-9.

PMID:
17883247
7.
8.

Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.

Nachtergael I, Gaspard N, Langlet C, Robberecht P, Langer I.

Cell Signal. 2006 Dec;18(12):2121-30. Epub 2006 Mar 27.

PMID:
16650965
9.

Mutation of the phosphorylatable residue Thr429 in Glu of the human VPAC1 led to a constitutively desensitized receptor.

Langlet C, Nachtergael I, Robberecht P, Langer I.

Peptides. 2006 Jul;27(7):1865-70. Epub 2006 Mar 22.

PMID:
16554109
10.

Activation of p38 and p42/44 MAP kinase in neuropathic pain: involvement of VPAC2 and NK2 receptors and mediation by spinal glia.

Garry EM, Delaney A, Blackburn-Munro G, Dickinson T, Moss A, Nakalembe I, Robertson DC, Rosie R, Robberecht P, Mitchell R, Fleetwood-Walker SM.

Mol Cell Neurosci. 2005 Dec;30(4):523-37. Epub 2005 Oct 3.

PMID:
16202621
11.

Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.

Xu L, Depoortere I, Vertongen P, Waelbroeck M, Robberecht P, Peeters TL.

Biochem Pharmacol. 2005 Sep 15;70(6):879-87.

PMID:
16076462
12.

Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling.

Langlet C, Langer I, Vertongen P, Gaspard N, Vanderwinden JM, Robberecht P.

J Biol Chem. 2005 Jul 29;280(30):28034-43. Epub 2005 Jun 2.

13.

Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor.

Langer I, Langlet C, Robberecht P.

J Mol Endocrinol. 2005 Apr;34(2):405-14.

PMID:
15821106
14.

Desensitization of the human motilin receptor by motilides.

Thielemans L, Depoortere I, Perret J, Robberecht P, Liu Y, Thijs T, Carreras C, Burgeon E, Peeters TL.

J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405. Epub 2005 Mar 11.

PMID:
15764739
15.

Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine.

Banks MR, Farthing MJ, Robberecht P, Burleigh DE.

Br J Pharmacol. 2005 Apr;144(7):994-1001.

16.

Identification and characterization of an endogenous chemotactic ligand specific for FPRL2.

Migeotte I, Riboldi E, Franssen JD, Grégoire F, Loison C, Wittamer V, Detheux M, Robberecht P, Costagliola S, Vassart G, Sozzani S, Parmentier M, Communi D.

J Exp Med. 2005 Jan 3;201(1):83-93. Epub 2004 Dec 28.

17.

Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells.

Langlet C, Gaspard N, Nachtergael I, Robberecht P, Langer I.

Peptides. 2004 Dec;25(12):2079-86.

PMID:
15572195
18.

Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation.

De Vriese C, Grégoire F, De Neef P, Robberecht P, Delporte C.

Endocrinology. 2005 Mar;146(3):1514-22. Epub 2004 Nov 24.

PMID:
15564328
19.
21.

Inhibitory pathways in the circular muscle of rat jejunum.

Vanneste G, Robberecht P, Lefebvre RA.

Br J Pharmacol. 2004 Sep;143(1):107-18. Epub 2004 Aug 9.

22.

Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites.

De Vriese C, Gregoire F, Lema-Kisoka R, Waelbroeck M, Robberecht P, Delporte C.

Endocrinology. 2004 Nov;145(11):4997-5005. Epub 2004 Jul 15.

PMID:
15256494
23.

Coexistence of non-adrenergic non-cholinergic inhibitory and excitatory neurotransmitters in a large neuronal subpopulation in the vaginal segment of the chicken oviduct.

Costagliola A, De Man JG, Majewski M, Lakomy M, Cecio A, Robberecht P, Pelckmans PA, Adriaensen D, Timmermans JP.

Auton Neurosci. 2004 May 31;112(1-2):37-48.

PMID:
15233929
24.

Ala-scan of ghrelin (1-14): interaction with the recombinant human ghrelin receptor.

Van Craenenbroeck M, Gregoire F, De Neef P, Robberecht P, Perret J.

Peptides. 2004 Jun;25(6):959-65.

PMID:
15203242
25.

Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.

Langer I, Gregoire F, Nachtergael I, De Neef P, Vertongen P, Robberecht P.

Peptides. 2004 Feb;25(2):275-8.

PMID:
15063009
26.

The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency.

Wittamer V, Grégoire F, Robberecht P, Vassart G, Communi D, Parmentier M.

J Biol Chem. 2004 Mar 12;279(11):9956-62. Epub 2003 Dec 29.

27.

Interaction of the growth hormone-releasing peptides ghrelin and growth hormone-releasing peptide-6 with the motilin receptor in the rabbit gastric antrum.

Depoortere I, Thijs T, Thielemans L, Robberecht P, Peeters TL.

J Pharmacol Exp Ther. 2003 May;305(2):660-7. Epub 2003 Feb 11.

PMID:
12606621
29.

Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists.

Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.

Neuropharmacology. 2003 Jan;44(1):125-31.

PMID:
12559130
30.
31.

A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.

Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.

Biochem Soc Trans. 2002 Aug;30(4):447-50. Review.

PMID:
12196112
32.

Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations.

Waelbroeck M, Perret J, Vertongen P, Van Craenenbroeck M, Robberecht P.

Biochem Soc Trans. 2002 Aug;30(4):437-41. Review.

PMID:
12196110
33.

Ribonucleotide reductase and thymidine phosphorylation: two potential targets of azodicarbonamide.

Fagny C, Vandevelde M, Svoboda M, Robberecht P.

Biochem Pharmacol. 2002 Aug 1;64(3):451-6.

PMID:
12147296
34.

Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.

Perret J, Vertongen P, Solano RM, Langer I, Cnudde J, Robberecht P, Waelbroeck M.

Br J Pharmacol. 2002 Aug;136(7):1042-8.

35.

Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity.

De Maria S, Metafora S, Metafora V, Morelli F, Robberecht P, Waelbroeck M, Stiuso P, De Rosa A, Cozzolino A, Esposito C, Facchiano A, Cartenì M.

Eur J Biochem. 2002 Jul;269(13):3211-9.

36.

VPAC(1) receptors have different agonist efficacy profiles on membrane and intact cells.

Langer I, Vertongen P, Perret J, Cnudde J, Gregoire F, De Neef P, Robberecht P, Waelbroeck M.

Cell Signal. 2002 Aug;14(8):689-94.

PMID:
12020769
37.

A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.

Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.

Mol Endocrinol. 2002 May;16(5):1089-96.

PMID:
11981043
38.
39.

Characterization of functional VIP/PACAP receptors in the human erythroleukemic HEL cell line.

Lema-Kisoka R, Hayez N, Langer I, Robberecht P, Sariban E, Delporte C.

Peptides. 2001 Dec;22(12):2155-62.

PMID:
11786204
40.

Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.

Juarranz MG, Bolaños O, Gutiérrez-Cañas I, Lerner EA, Robberecht P, Carmena MJ, Prieto JC, Rodríguez-Henche N.

Cell Signal. 2001 Dec;13(12):887-94.

PMID:
11728828
41.

Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.

Langer I, Perret J, Vertongen P, Waelbroeck M, Robberecht P.

Cell Calcium. 2001 Oct;30(4):229-34.

PMID:
11587546
42.

Could capillary zone electrophoresis of tryptic peptides be used for the characterization of hemoglobin variants?

Lin C, Gulbis B, Delobbe E, Robberecht P, Cotton F, Fontaine B, Vertongen F.

Hemoglobin. 2001 Aug;25(3):259-72.

PMID:
11570719
43.

Evidence that the chromogranin B fragment 368-417 extracted from a pheochromocytoma is phosphorylated.

Dahma H, Gourlet P, Vandermeers A, Vandermeers-Piret MC, Robberecht P.

Peptides. 2001 Sep;22(9):1491-9.

PMID:
11514034
44.

Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure.

Vertongen P, Solano RM, Juarranz MG, Perret J, Waelbroeck M, Robberecht P.

Peptides. 2001 Sep;22(9):1363-70.

PMID:
11514016
45.

Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.

Vertongen P, Solano RM, Perret J, Langer I, Robberecht P, Waelbroeck M.

Br J Pharmacol. 2001 Aug;133(8):1249-54.

46.

Different domains of the VIP receptors modulate agonist affinity and intrinsic activity.

Juarranz MG, Van Rampelbergh J, Gourlet P, Waelbroeck M, Robberecht P.

Ann N Y Acad Sci. 2000;921:395-9. No abstract available.

PMID:
11193863
47.

Sequences (103-110) and (116-120) of the rat secretin receptor are implicated in secretin and VIP recognition.

Robberecht P, Di Paolo E, Moguilevsky N, Bollen A, Waelbroeck M.

Ann N Y Acad Sci. 2000;921:362-5. No abstract available.

PMID:
11193853
48.

VIP and PACAP 38 modulate ibotenate-induced neuronal heterotopias in the newborn hamster neocortex.

Gressens P, Arquié C, Hill JM, Marret S, Sahir N, Robberecht P, Evrard P.

J Neuropathol Exp Neurol. 2000 Dec;59(12):1051-62.

PMID:
11138925
49.

Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.

Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.

Peptides. 2000 Oct;21(10):1543-9.

PMID:
11068102
50.

Evidence for VIP(1)/PACAP receptors in the afferent pathway mediating surgery-induced fundic relaxation in the rat.

Boeckxstaens GE, Hollmann M, Heisterkamp SH, Robberecht P, de Jonge WJ, van Den Wijngaard RM, Tytgat GN, Blommaart PJ.

Br J Pharmacol. 2000 Oct;131(4):705-10.

Supplemental Content

Loading ...
Support Center